Core Insights - Thermo Fisher exceeded analysts' expectations for third-quarter revenue and profit, driven by robust demand for its tools and technologies used in therapy development [1] Financial Performance - The company reported strong financial results, indicating a positive trend in revenue and profit growth compared to previous quarters [1] Market Demand - There is a significant increase in demand for Thermo Fisher's medical equipment, reflecting broader trends in the healthcare and biotechnology sectors [1]

Accessibility StatementSkip Navigation MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ --Â Boston Scientific Corporation (NYSE:Â BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational basis and 15.3 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 m ...

Core Insights - Perimeter Medical Imaging AI, Inc. is participating in the American Society of Breast Surgeons' Annual Strategic Futures Forum to engage with leaders in the breast surgery community and enhance patient care [1][2] - The theme of this year's Forum is "Building the Breast Care Team," focusing on multi-disciplinary collaboration to improve patient outcomes [2][3] Company Overview - Perimeter Medical Imaging AI is a commercial-stage medical technology company based in Toronto and Dallas, specializing in advanced imaging tools for cancer surgery [4] - The company offers the FDA-cleared Perimeter S-Series OCT system, which provides real-time visualization of excised tissues at the cellular level [4] - The investigational Perimeter B-Series OCT with ImgAssist AI is currently under evaluation in a pivotal clinical trial, supported by a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas [4] Industry Context - The American Society of Breast Surgeons (ASBrS) has over 4,000 members globally and aims to optimize patient outcomes through education, innovation, research, and advocacy [3]

Core Viewpoint - Private equity firms Blackstone and TPG are acquiring Hologic for over $13 billion, taking the company private with a share price of up to $79, representing a 46% premium from late May [1][2]. Deal Structure - The acquisition includes $76 in cash per share, with additional payments contingent on revenue goals from Hologic's breast health business, bringing the total deal value to $18.3 billion when factoring in Hologic's $2.2 billion in cash and short-term investments and $2.5 billion in debt [2]. Regulatory and Approval Status - The deal requires approval from regulators and Hologic shareholders, but has already received unanimous approval from Hologic's board. The transaction is expected to close in the first half of next year [3]. Market Reaction - Following the announcement, Hologic shares increased nearly 4% to $74.62, while broader market indexes showed mixed performance [5]. Post-Transaction Details - After the acquisition, Hologic will be delisted from the Nasdaq stock exchange but will retain its name and headquarters in Marlborough, Massachusetts [5].

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific Launches Innovative Carbon Calculator to Drive Greener Clinical Trials. ...

Core Insights - Baird Medical Investment Holdings Ltd. is a global leader in minimally invasive Microwave Ablation (MWA) technology and has successfully participated in a workshop in Malaysia aimed at advancing MWA skills among local physicians [1][3]. Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments [4]. - The company is FDA 510(k)-certified and its solutions are utilized in over 30 prestigious hospitals and clinics in the United States, including Johns Hopkins Hospital and Weill Cornell Medicine [4]. - Baird Medical is the market leader in China for thyroid microwave ablation devices and consumables, with a growing commercial presence in over 20 countries [4]. Workshop Details - The workshop held on October 1-2, 2025, featured leading surgeons and endocrinologists, providing hands-on training and complex case discussions [2]. - The program was led by distinguished faculty, including Dr. Shuhang Xu from Nanjing University and local surgeons from HCTM [2]. Commitment to Innovation - Baird Medical's participation in the workshop underscores its commitment to advancing medical technologies and ensuring their effective adoption globally [3]. - The company aims to empower physicians to deliver MWA treatments safely and effectively, marking a significant step in the global expansion of this therapy [3].

Core Insights - Zimmer Biomet Holdings, Inc. is showcasing its innovations in robotics and musculoskeletal solutions at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS) [1][2] - The company emphasizes the urgency for advanced orthopedic solutions due to an aging population and rising patient expectations for less disruption and faster recovery [3] Product Highlights - The mBôsâ™ TKA System is a CT-based, semi-autonomous robotic technology for total knee arthroplasty that has received FDA 510(k) clearance, with a fully autonomous version in clinical trials [7] - The ROSA Knee with OptimiZe™ is the latest version of the ROSA Knee System, pending FDA clearance, designed to enhance surgical planning and accuracy [7] - The TMINI Miniature Robotic System is a handheld, wireless CT-based robotic system for precise implant placement [7] - ZBEdge Analytics provides intra-operative insights via a smartphone application, allowing surgeons to assess performance and clinical decisions [7] - The mymobility Care Management Platform offers continuous data and patient feedback to improve surgical preparation and recovery [7] - The Oxford Cementless Partial Knee is the only FDA-approved mobile cementless partial knee implant in the U.S., known for its efficiency and survivorship [7] - The Persona OsseoTi Keel Tibia is a cementless tibia for TKA featuring a 3D printed porous tray for stable fixation [7] - The Persona® SoluTion™ PPS® Femur is designed for patients with metal sensitivities, featuring a porous coating for cementless fixation [7] - Persona IQ The Smart Knee captures patient-specific metrics for post-operative insights, enhancing the TKA patient experience [7] Strategic Vision - The company aims to lead in orthopedic innovation by integrating robotics, digital platforms, and AI to improve surgical precision and patient outcomes [3][9] - Zimmer Biomet's commitment to innovation is highlighted as the most ambitious cycle in its history, positioning it to deliver comprehensive orthopedic solutions [3]

Tianyi Yan +86(21)2401-8609 | tianyi.yan@goldmansachs.cn Goldman Sachs (China) Securities Company Limited 20 October 2025 | 6:17PM CST Equity Research United Imaging (688271.SS): Quantify China PCCT market potential; TP up to Rmb175; Buy CT scanner is the largest category by bidding value among medical imaging equipment in China. Recently, with the NMPA approval of domestic Photon-Counting CT (PCCT) from United Imaging and Neusoft on the same day (Aug 26, 2025), as well as the strong sales performance of Si ...

Core Insights - Accuray Incorporated is undergoing a significant organizational, strategic, and operational transformation to enhance competitiveness and drive sustainable growth [1][3] - Steve La Neve has been appointed as the new CEO, succeeding Suzanne Winter, who will retire after six years [2][3] - The transformation plan aims to increase operating margins and improve organizational agility, with most initiatives set to be implemented in the current fiscal year [1][3] Leadership Changes - Steve La Neve brings over 40 years of medical-technology experience and a proven track record in operational excellence and revenue growth [3][4] - Steven F. Mayer has been appointed as Transformation Board Sponsor to oversee the execution of the transformation initiatives [5][6] - Chan W. Galbato has been nominated to the Board of Directors, bringing over 30 years of operational and strategic leadership experience [7] Financial Performance - Accuray expects total revenues for the fiscal 2026 first quarter to be between $92.5 million and $94 million, with service revenues exceeding plans but product revenues falling short in EIMEA and China [8][9] - The company anticipates reaching a high single-digit adjusted EBITDA margin run-rate within twelve months, aiming for double-digit margins in the medium to long term [6][8]

Core Insights - Baird Medical Investment Holdings Ltd. participated in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism, highlighting its leadership in minimally invasive Microwave Ablation (MWA) technology [1][3][4] - The workshop, chaired by Prof. Ming'an Yu, served as a platform for experts to share clinical experiences and advanced techniques in the field [2] - Baird Medical emphasizes the importance of collaboration in advancing MWA innovation and improving patient care [4] Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on surgical robotic systems and innovative surgical instruments [6] - The company is FDA 510(k)-certified and has its solutions utilized in over 30 prestigious hospitals in the U.S., including Johns Hopkins Hospital and Columbia University Medical Center [6] - Baird Medical is the market leader in China for thyroid microwave ablation devices and is expanding its presence in over 20 countries [6]